Peterfy Sandor Utcai Korhaz Rendelointezet
- Address
- Peterfy Sandor Utca 8-20/ VII, Kerulet, 1076 Budapest, Hungary
Cardiovascular Diseases Research
The Neurology department at Peterfy Sandor Utcai Korhaz Rendelointezet is conducting studies aimed at reducing the impact of Acute Ischemic Stroke and high‑risk transient ischemic attacks. These trials explore innovative approaches to lower the chance of a repeat stroke in patients with underlying Cardiovascular Diseases.
- Assessing the potential of the oral anticoagulant milvexian to prevent further ischemic events.
- Comparing outcomes with standard care to determine added benefit.
- Monitoring safety signals to ensure tolerability in a stroke‑prone population.
Four investigators oversee the two ongoing trials, aiming to inform future treatment guidelines for stroke prevention.
Virus Diseases Research
In collaboration with pediatric specialists, the site evaluates strategies to protect infants from severe Respiratory syncytial virus (RSV) infection. The focus is on children at elevated risk due to underlying health conditions.
- Testing the safety and tolerability of the monoclonal antibody clesrovimab (MK‑1654) as an alternative to existing prophylaxis.
- Directly comparing adverse event rates with the established antibody palivizumab.
- Evaluating efficacy in reducing RSV‑related hospitalizations among high‑risk infants.
The trials involve a small team of four investigators and aim to expand preventive options for RSV across Europe.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Micurx Pharmaceuticals Inc.1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 332 other sites in Hungary
Therapeutic Area Benchmark — Hungary
Select a therapeutic area to compare against other sites in Hungary.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Hungary
Market Share
Country: Hungary
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Peterfy Sandor Utcai Korhaz Rendelointezet
lock Showing 1 of 4 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Contezolid Acefosamil and Contezolid Compared to Linezolid Administered Intravenously and Orally to Adults with Moderate or Severe Diabetic Foot Infections | Micurx Pharmaceuticals Inc. | Phase III | Recruiting | Mar 2023 | — |
IMP list
lock Showing 1 of 14 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Sodium Chloride | 2 | Unknown | 2021-11-25 | 2024-03-25 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.